CSF3 and graft versus host disease: As shown in the current cohort, however, G-CSF/ATG/LD-PTCy protocol did lower the incidence of GVHD without imperiling potent engraftment in haplo-HSCT for SAA patients, which can hopefully further improve the therapeutic effect and expand the donor pool.